Agios scores its sec­ond new drug ap­proval, ivosi­denib heads to the AML mar­ket

Agios has hit an­oth­er big goal in its decade-long track record. The FDA to­day sig­naled the ac­cel­er­at­ed ap­proval of ivosi­denib (AG-120) for ad­vanced acute myeloid leukemia.

This marks the sec­ond drug ap­proval for Agios, a biotech com­pa­ny found­ed by David Schenkein, which he’s fond of say­ing got start­ed with a “blank sheet of pa­per.”

That sheet is get­ting quite crowd­ed now.

The new drug will be mar­ket­ed by Agios as Tib­so­vo, and the com­pa­ny is charg­ing $26,115 for a one-month sup­ply. Agios shares $AGIO were down just slight­ly — this was no great sur­prise — but the stock is up 56% 0f where it was a year ago.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.